Navigation Links
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Date:5/18/2008

ant difference in overall survival between the RAD001 and placebo groups (hazard ratio = 0.83 with 95% CI 0.50 to 1.37; p-value = 0.23). The study design allowed patients to be unblinded at the time of radiological disease progression; patients receiving placebo were allowed to cross over to receive RAD001. There was no significant difference in objective response rate between the RAD001 and placebo groups (1% vs. 0% of responders). However, in a central review among patients evaluable for best percentage change in target lesions (223 and 107 in RAD001 and placebo arms, respectively), tumor shrinkage was observed in 50% of patients receiving RAD001 during the double- blind portion of the study versus 8% of patients receiving placebo. Quality of life measurements taken throughout the study showed no significant difference between the RAD001 and placebo groups.

Safety findings in the study were consistent with those seen in prior Phase II studies. The most frequent adverse events in patients who took RAD001 included mouth sores (40%), feelings of weakness (37%), and rash (25%). There was a low incidence of grade 3 or 4 drug-related adverse events (greater than or equal to 1% of patients listed): mouth sores (3%), lung inflammation (3%), infection (3%), tiredness/feelings of weakness (4%), diarrhea (1%), mucosal inflammation (1%), and difficulty breathing (1%). The trial had a low rate of adverse drug reactions leading to discontinuation among patients who took RAD001 (6%).

About renal cell carcinoma (RCC)

In the United States, kidney cancer accounts for approximately 3% of all adult cancers. RCC, the most common type of kidney cancer, accounts for approximately 90% of malignant kidney tumors. In RCC, cancer cells develop in the lining of the kidney's tubes and grow into a tumor.

About RAD001

RAD001, an oral inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 inhibits mTOR, a pr
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
3. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
4. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
5. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lbvqqr/global_ultrasound ) ... Ultrasound Equipment Market 2015-2019" report to their ... Ultrasound Equipment market to grow at a CAGR ... Ultrasound equipment are used to examine organs using ... by cardiologists, radiologists, surgeons, obstetricians, and many other ...
(Date:3/3/2015)... 2015  Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced it will participate ... 11, 2015, in Miami . ... Executive Officer, will speak at 1:05 PM Eastern Time.  ... format, and no formal materials will be presented.  A ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
Breaking Medicine Technology:Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
... , April 26, 2010 Thanks to promising,commercial debut of ... Technologies service offer (fully,integrated and automated patient/product tracking and supply chain) IMPLANET,S.A. ... ). , , , ... IMPLANET is proud to welcome a reference new institutional investor,CM-CIC Private ...
... April 26 Sirion Therapeutics, Inc., a privately ... gel) 0.15% is now commercially available.  Zirgan™, which was approved ... 2009 , is a topical ophthalmic antiviral indicated for the ... , , ...
Cached Medicine Technology:IMPLANET Raises Additional EUR 8 Million (USD 11 Million) to Fuel Deployment 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:3/3/2015)... 03, 2015 US Air Purifiers LLC ... purification systems, is pleased to announce that all Rabbit brand ... interruption related to the west coast port strikes. This news ... the corner. , The port strikes, which ... slow fourth quarter economic growth by as much as 1%, ...
(Date:3/3/2015)... March 03, 2015 The first week ... National Sleep Foundation. The event brings recognition to a ... , According to the Centers for Disease ... of one form or another. Too little or unrestful ... of physical illness and depression, and even a higher ...
(Date:3/3/2015)... 03, 2015 Today is International Ear ... using the occasion to applaud and promote the launch ... World Health Organization (WHO) for stemming the threat of ... encourage young people to practice safe listening when they ... concerts or sporting events, or engaging in other forms ...
(Date:3/3/2015)... 2015 The number of couples experiencing ... about 15%. This increases to 50% by the time ... JL, Yuzpe AA, et al. Estimating the prevalence of ... Jason Hitkari, a reproductive endocrinologist and co-director at Olive ... and clinical director and founder of Acubalance Wellness Centre ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 -- vRad ( ... radiology practice, today announced that Arlene Sussman, MD, a ... host a live webinar to explore how telemedicine best ... breast imaging services for women virtually anywhere. Click ... Imaging Service Line” on March 4, 2015 at 1:00 ...
Breaking Medicine News(10 mins):Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:ASHA Applauds Launch of New WHO Campaign 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4
... But some mental-health experts dispute the findings , , TUESDAY, ... as Prozac are widely prescribed for people with varying ... those with the most severe depression, a new study ... antidepressants, they also get better when they take a ...
... Wealthy Suburbanites Equal High Demand for Medical ... HealthLeaders-InterStudy, NASHVILLE, Tenn., Feb. 27 HealthLeaders-InterStudy, ... health,systems, eager to gain an advantage in the ... new facilities and completing mergers.,According to the newly ...
... Sooner, ASPS Study Says, ARLINGTON HEIGHTS, Ill., ... Americans, skin may keep its youthful appearance longer,than ... show,facial aging in the outer corner of the ... Reconstructive Surgery(R) (PRS), the,official medical journal of the ...
... Satisfaction with GlaxoSmithKline,s Advair and,Boehringer Ingelheim/Pfizer,s Spiriva, ... Drug, According to a New Report from ... Decision Resources, one of the,world,s leading ... and,healthcare issues, finds that surveyed physicians indicate ...
... Materials, Fuel, ... Food, ... ),today announced leadership changes to strengthen its leading biotechnology,position and better ... materials, food, feed and fuel markets., "Across its business segments, ...
... Center to Provide Increased High-Performance ... to Korean Industry and Academia, SOUTHPOINTE, Pa., ... a global innovator of simulation software and technologies,designed ... Korean Institute of Science and Technology Information (KISTI), ...
Cached Medicine News:Health News:Only Severely Depressed Benefit From Antidepressants: Study 2Health News:Mergers and New Facilities Abound in Washington, D.C. Suburbs 2Health News:African Americans Show Facial Aging in Eyes Earlier Than Caucasians 2Health News:A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status 2Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 2Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 3Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 4Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 2Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 3Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 4
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Great for small incisions and excision needs...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
2.5mm...
Medicine Products: